Bloomberg Technology
BioAge Labs Raises $170m to Develop Therapies Using AI
BioAge Labs, a clinical-stage biotechnology company developing therapies for obesity and metabolic disease thanks to their AI-powered discovery platform, raised $170 million in an oversubscribed series D financing round led by Sofinnova Investments. Kristen Fortney, BioAge CEO and Co-Founder, joins Ed Ludlow and Caroline Hyde on “Bloomberg Technology.” ——– Like this video? Subscribe to Bloomberg…
@ponokealii
February 13, 2024 at 3:05 pm
We already have the answers to solving the problem of our imposed accelerated aging process and the devastating and life threatening potential of disease.
We KNOW that our human genome has been artificially edited and manipulated to shorten our lifespan – limiting our naturally unlimited lifespan to just 120 years –
We suspect that this genome manipulation was done by one of our progenitors, most likely the Annunaki.
The evidence is readily apparent by looking at the second and third genomes in the human genome sequence which have been artificially fused together.
This is not part of a natural evolutionary process but clearly an example of deliberate artificial gene manipulation.
We now possess the ability to manipulate our own human genome far beyond what is being made publicly known.
The answers to extending our lifetime to theoretical infinity and to ending disease is in our own hands.
Immortality and perfect health are perfectly attainable.
We have all the tools necessary and understand the methods and processes to edit the human genome for the benefit of all humanity.
We only need the wisdom, foresight and courage to do what must be done.
Ponokeali’i